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Rab GTP-binding proteinCannabinoid receptor 2 (CB2) is a GPCR highly expressed on the surface of cells of the immune system,
supporting its role in immunomodulation. This study has investigated the trafﬁcking properties of this
receptor when stably expressed by HEK-293 cells. As previously reported, cell surface CB2 rapidly internalized
upon exposure to agonist. Direct evidence of CB2 recycling was observed upon competitive removal of the
stimulating agonist by inverse agonist. CB2 also underwent slow constitutive internalization when agonist
was absent and was up-regulated in the presence of inverse agonist. Co-expression of CB2 and dominant
negative Rab5 resulted in a signiﬁcantly reduced capacity for receptors to internalize with no effect on
recycling of the internalized receptors. Conversely, co-expression with dominant negative Rab11 did not alter
the ability of CB2 to internalize but did impair their ability to return to the cell surface. Co-expression of wild-
type, dominant negative or constitutively active Rab4 with CB2 did not alter basal surface expression, extent
of internalization, or extent of recycling. These results suggest that Rab5 is involved in CB2 endocytosis and
that internalized receptors are recycled via a Rab11 associated pathway rather than the rapid Rab4 associated
pathway. This report provides the ﬁrst comprehensive description of CB2 internalization and recycling to
date.nnabinoid receptor 2; DMEM,
rum; GPCR, G-protein coupled
dney; PBS, phosphate buffered
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The intense interest in cannabinoid receptor 2 (CB2) as a target for
the treatment of inﬂammatory conditions, neuropathic pain and a
variety of other pathologies, coupled with an increase in the range and
availability of cannabinoid receptor agonists and antagonists [1],
suggests that CB2-speciﬁc ligands are likely to progress from animal
studies to clinical trial in the near future. Intracellular trafﬁcking
pathways control the subcellular distribution of receptors and thereby
are fundamental contributors to the ability of receptor ligands to
generate effective responses. Improvedunderstandingof CB2 trafﬁcking
will therefore provide insight into the responses generated in vitro and
in vivo and may aid in formulation of dosing regimes or lead to the
identiﬁcation of novel drug targets with potential to modulate CB2
function indirectly.Agonist binding induces conformational changes in G-protein
coupled receptors (GPCRs), promoting coupling to intracellular proteins
and initiating signaling cascades. This also leads to desensitization and
internalization of activated receptors as adaptive features, disabling
cellular responses to continued agonist exposure. Current studies
detailing the trafﬁcking properties of CB2 are limited but clearly indicate
that CB2 undergoes phosphorylation [2,3] and internalization following
agonist stimulation [2,4,5] or exposure to UVB radiation [6]. The
observation that CB2 is repeatedly phosphorylated and dephophory-
lated by alternate stimulationwith agonist and inverse agonist indicates
that CB2 recycling may occur [2], but direct evidence to support this
hypothesis is lacking.While these prior studies have demonstrated that
agonist-induced internalization occurs, the mechanisms controlling
internalization have not yet been identiﬁed, nor has the post-endocytic
fate of CB2 been investigated directly.
The Rab proteins are the largest family belonging to the Ras
superfamily of small GTPases and are involved in numerous trafﬁcking
processes throughout the cell [7]. They are tethered to membranes by
lipid groups attached to their C-termini and bind GTP in their active
state. Hydrolysis of GTP to GDP converts the Rab to an inactive form.
Rabs predominantly exist in an active state (GTP-bound) as GDP is
rapidly replaced by GTP which is at a high cytosolic concentration [7].
Some of the key Rabs that have been identiﬁed to facilitate the transport
ofmembrane associated receptors are Rab4, 5, and 11. Speciﬁcally, Rab5
1555N.L. Grimsey et al. / Biochimica et Biophysica Acta 1813 (2011) 1554–1560is associated with internalization of clathrin coated pits and fusion with
early endosomes [8,9]; it is therefore locatedon the cytoplasmic surfaces
of the plasma membrane, clathrin coated pits and vesicles, and early
endosomes. Rab5 has been demonstrated to be involved in the
endocytosis of cannabinoid receptor 1 (CB1) [10] as well as several
other GPCRs [7]. CB1has also been suggested to associatewithRab4 [10]
which is generally considered to facilitate rapid recycling of receptors
directly from the early endosomes back to the plasma membrane [11],
although the ability of CB1 to recycle has been questioned recently [12].
Rab11 was not associated with CB1 trafﬁcking [10] but has been
indicated to be involved in the slow recycling of GPCRs via the
perinuclear recycling compartment [13]. This study has examined the
fate of internalized CB2 and its interactions with Rab proteins with a
view to understanding the regulation of CB2 cell surface expression.
2. Materials and methods
All reagents were purchased from Invitrogen (Carlsbad, CA) unless
otherwise stated.
2.1. HEK-293 cell line generation and maintenance
HEK-293 cells were purchased from the ATCC (#CRL-1573) and
maintained in DMEM supplemented with 10% fetal bovine serum, 100
units/mL penicillin and 100 μg/mL streptomycin. A pcDNA3.1 vector
encoding human CB2 with three hemeagglutinin (HA) tags at the
receptor N-terminus was purchased from the Missouri S&T cDNA
Resource Center (www.cdna.org; #CNR020TN00) and the 3xHA CB2
sequence was subcloned using restriction enzymes KpnI (Roche,
Mannheim, Germany) and PmeI (New England Biolabs, MA, USA) into
the pEF4-V5-HisA vector. This vector was stably transfected into HEK-
293 cells with Lipofectamine™ 2000 according to the manufacturer's
instructions. Following antibiotic selection, a mixed population of cells
expressing 3xHA hCB2 was isolated by ﬂow cytometry. Brieﬂy, cells
were dislodged with Versene and labeled with mouse-anti-HA.11
antibody (anti-HA.11; MMS-101P, Covance, Berkeley, CA, USA).
Cells were then pelleted by spinning at 500×g and resuspended in
goat-anti-mouse Alexa 488 ﬂuorescent secondary antibody (Molecular
Probes, Eugene, OR, USA) in phenol red freeDMEMon ice. Afterwashing
twice in PBS cells were resuspended in phenol red-free DMEM and
passed through a 24-gauge needle to ensure a single suspension before
passing through a Becton Dickinson FACS Vantage™ (BD Biosciences,
Franklin Lakes,NJ). UsingCellQuest Pro software (BD, Franklin Lakes,NJ)
a pool of cells withmoderate cell surface ﬂuorescencewas gated for and
collected. The resulting mixed culture is referred to as HEK-CB2 from
this point. This cell line was maintained in the presence of 250 μg/mL
Zeocin™.
2.2. Trafﬁcking experiments
HEK-CB2 cells were seeded at 26,000–28,000 cells/well in poly-
L-lysine (Sigma-Aldrich, St. Louis, MO) treated 96-well plates
(Thermo Fisher Scientiﬁc, Nunc GmBH, MA, USA) 18–36 hours prior to
stimulation. ExperimentswithHEK-CB2 cellswere performed inDMEM
with 5 mg/mL bovine serum albumin (ICPbio, Auckland, New Zealand)
(basal media) and stimulations took place at 37 °C with 5% CO2. Tubes
and dispensing vessels for cannabinoid and vehicle containing media
were silanized and rinsed with deionized water prior to use (Coatasil;
Ajax Finechem, Sydney, NSW, Australia).
Prior to cannabinoid stimulation cells were equilibrated in basal
media for 30 minutes and then incubated with anti-HA.11 at 1:500
dilution in basalmedia for 30 minutes. Following two brief washeswith
warm basal media cells were stimulatedwith indicated drugs (HU-308,
gifted by Professor Raphael Mechoulam, Hebrew University, Jerusalem;
AM630, Tocris Bioscience, Bristol, UK). Between stimulations cells were
washed twice with basal media. After the appropriate stimulation timeplateswere placed on ice for 90 seconds to rapidly cool the cells and halt
membrane trafﬁcking. Cells were then incubated with Alexa 488 goat–
anti-mouse ﬂuorescent secondary antibody at 1:250 in basal media for
30 minutes at room temperature. Subsequently wells were washed
twicewith basal media, ﬁxed in 4% paraformaldehyde for 10 minutes at
room temperature, and washed with phosphate buffered saline (PBS).
For some experiments a second ﬂuorescent goat-anti-mouse
secondary antibody (Alexa 594, Molecular Probes) was incubated
with ﬁxed and permeabilized cells to detect anti-HA.11 antibody that
was located intracellularly, as well as on the cell surface (total starting
cell surface receptor). This antibody was diluted to 1:400 in PBS with
0.2% Triton® X-100, 1% normal goat serum and 0.4 mg/mL thiomersal
(Merck, Darmstadt, Germany), and incubated at room temperature for
3 hours followed by three washes in PBS with 0.2% Triton® x-100. Cell
nuclei were labeled with Hoechst 33258 (Sigma-Aldrich).
2.3. Transient transfection with Rab expressing vectors
Some experiments required transient transfection of HEK-CB2
cells with vectors prior to stimulation. For these, cells were seeded
directly into a transfection mixture containing 2.5 μg DNA and 10 μl
Lipofectamine™ 2000 per ml Opti-MEM®, prepared according to the
manufacturer's instructions. 96-well plates were pre-treated with
poly-L-lysine and 50 μl/well transfection mix added to wells before
HEK-CB2 cells were seeded at 45,000 cells/well. After 48 hours, cells
were stimulated, ﬁxed, imaged and analyzed as described below.
The vectors containing N-terminally EGFP tagged Rab sequences for
Rab4b, 5a or 11a were kindly gifted by Professor Robert Lodge of the
Univeristé Laval, Canada. Three variations of each EGFP taggedRabwere
used. Wild-type Rabs (Rab WT) contained no mutations. Dominant
positive Rabs (Rab GTP) contained a single mutation (Q67L in Rab4,
Q79L in Rab5, and Q70L in Rab11), conferring an inability to hydrolyse
GTP thereby being constitutively active [14]. Dominant negative Rabs
(Rab GDP) contained a single mutation (S22N in Rab4, S34N in Rab5,
and S25N in Rab11), causing the resulting protein to be constitutively
inactive, preferentially binding GDP [14].
2.4. Image acquisition and analysis
Image acquisition and analysis was based on previously described
methods [15]. Brieﬂy, images were acquired with a Discovery-1TM
automated ﬂuorescence microscope (Molecular Devices, Sunnyvale,
CA) using DAPI (350Ex/465Em), FITC (470Ex/535Em), and TRED
(560Ex/650Em) ﬁlter sets. Grayscale images were captured at 100×
magniﬁcation from four sites per well with at least four replicate wells
for each stimulation condition. Images that were not focused correctly
or included large ﬂuorescent debris were excluded from data analysis.
Metamorph® software (v. 6.2r6, Molecular Devices) was utilized for
image analysis. The total gray value per cell was calculated by
determining total gray value above background for each image and
dividing it by the number of cells present. The number of cells was
determined using the “Count Nuclei” in-built Metamorph® assay and
the total gray value above background was determined using the
“ThresholdedAverage Intensity” journal described byGrimsey et al.[15].
As variation in the intensity of antibody staining and therefore
ﬂuorescent signal exists between experiments, normalization to
unstimulated controls was necessary to combine results from repeated
stimulations. GraphPad Prism (v. 4.02, GraphPad Software)was utilized
to generate graphs, ﬁt appropriate models and perform statistical tests.
Comparisons were performed using a one- or two-way ANOVA with
Bonferroni post-test when signiﬁcance was reached.
For analysis of the Rab co-expression experiments, basal CB2 cell
surface expression in cells transfected with each of the nine different
Rab proteinswas normalized to cell surface CB2 in cells transfectedwith
vector containing EGFP alone. To determine the extent of internaliza-
tion, the level of cell surface receptor remainingafter 30 minutes agonist
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the same Rab protein. The relative extent of receptor recycling was
determined by normalizing the cell surface levels of receptor after
agonist stimulation and subsequent agonist washout to the starting
(100%) andpost-internalization (set to 0%) surface expression levels. An
agonist washout timepoint at which recycling was sub-maximal
(20 minutes) was chosen so that both increases and decreases in the
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Fig. 2. Agonist washout conditions for CB2 recycling in HEK-CB2 cells. Surface receptor
was labeled with primary antibody, then stimulated for 30 minutes with 1 μM HU-308
(“Internalized”). Cells were then washed three times and incubated with AM630
(10 μM) or vehicle for 60 minutes. Secondary antibody was applied under non-
permeabilizing conditions to detect antibody-labeled receptor on the cell surface at the
end of the drug stimulation. Recycling was observed following agonist-induced3. Results
3.1. CB2 agonist-induced internalization
Agonist-induced CB2 internalization was both concentration and
time dependent (Fig. 1A and B). Corresponding with a reduction in
cell surface labeling, CB2 was internalized to diffusely scattered
endosomes as well as a distinct perinuclear clustering of receptors
(Fig. 3Bii). Agonist-induced loss of cell surface receptor following a
120 minute stimulation with varying concentrations of HU-308
exhibited a classical sigmoidal shaped curve and an EC50 value of
14.6±5.3 nM (Fig. 1A) which is comparable with published potency
values for inhibition of cAMP [16]. At the highest concentrations of
agonist used and time points greater than 30 minutes using 1 μMHU-
308 a plateau was reached with 30–40% of receptors remaining on the
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Fig. 1. Internalization of CB2 in HEK-CB2 cells. (A) Concentration dependence of CB2
receptor loss from the cell surface upon endocytosis induced with CB2-speciﬁc agonist
HU-308 at varying concentrations for 120 minutes, n=4. (B) Receptor loss from the cell
surface induced by 1 μM HU-308 with respect to time, n=3. Data was normalized to
the cell surface signal of vehicle-treated cells and is presented as means±SEM of the
indicated number of independent experiments (n).
internalization when media for the ﬁnal 60 minute incubation contained AM630, but
not with vehicle only. Data was normalized to the cell surface CB2 expression level of
unstimulated cells and is presented as means±SEM of three independent experiments.3.2. CB2 recycling
Cannabinoid ligands are highly lipophilic and likely to permeate
lipid membranes. Thus, removing media after HU-308 stimulation
may leave behind lipid solubilized ligand at concentrations high
enough to continue to internalize receptors. Indeed, washing with
basal media alone was not sufﬁcient to allow for CB2 recycling and the
addition of inverse agonist, AM630, was necessary to enable recycling
to be visualized (Fig. 2). After internalizing CB2 for 30 minutes with
1 μM HU-308, washing, and applying AM630, the cell surface was
replenished to approximately 80% of basal cell surface expression
with a half-time of 7.8±3.4 minutes (one-phase exponential associ-
ation from 0 minutes; Fig. 3). When secondary antibody was applied
under permeabilizing conditions, no reduction in the total immuno-
ﬂuorescence was observed (p=0.2273; Fig. 3), indicating that
internalized CB2 was not degraded during the time course studied.
Chronic agonist stimulation has been reported to induce a switch
from recycling to degradative pathways for some GPCRs [17–19]. We
found that after chronic agonist stimulation (4 hours) CB2 was still
able to recycle with no evidence of degradation of internalized
receptors (Fig. 4). The role of the proportion of receptors that
apparently remains sequestered in the cytoplasm following internal-
ization is not yet clear and requires additional investigation.
3.3. CB2 constitutive trafﬁcking
CB2 also underwent internalization when agonist was absent,
however, at a much slower rate. Over the time course studied, the
process resembled a linear function and receptors were endocytosed
at a rate of 5.8±0.2% per hour (Fig. 5A). Constitutively endocytosed
CB2 appeared to be degraded, as demonstrated by a reduction in the
primary antibody-tagged receptor present in the whole cell over time
(Fig. 5A).
Given this constitutive internalization, application of an inverse
agonist would be expected to upregulate surface CB2 by stabilizing
receptor in an inactive state and thereby preventing endocytosis.
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Fig. 3. Recycling of anti-HA labeled CB2 in HEK-CB2 cells. (A) Surface receptor was labeled with primary antibody, then internalized for 30 minutes with 1 μMHU-308. Cells were rapidly
washed three times and incubatedwithAM630 (10 μM) for the times indicated. Secondary antibodywas applied under non-permeabilizing conditions to detect antibody-labeled receptor
on the cell surface at theendof thedrug stimulation (demonstratingCB2 recycling following agonist-induced internalization,□), or underpermeabilizing conditions todetect total primary
antibody-labeled receptor (demonstrating a lackof CB2 degradation following internalization,■). Datawas normalized to the expression level of unstimulated cells and is presented as the
means±SEM of three independent experiments. (B) (i) HEK-CB2 cells were live labeled with anti-HA.11 antibody and not stimulated, (ii) incubatedwith 1 μMHU-308 for 30 minutes to
induce internalization, or (iii) incubated with HU-308 1 μM for 30 minutes followed by a 60 minute incubation with AM630 (10 μM) to induce recycling. All cells were ﬁxed and
permeabilized for detection of intracellular as well as cell surface CB2. Inset details diffusely scattered endosomes (arrowheads) and perinuclear receptor cluster (arrow). Scale bar
represents 20 μm.
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Fig. 4. Effect of chronic HU-308 stimulation on CB2 recycling. Surface receptorwas labeled
with primary antibody, then stimulated for 4 hours with 1 μM HU-308 (“Internalized”).
Cells were washed three times and incubated with AM630 (10 μM) for 60 minutes
(“Recycled”). Secondary antibody was applied under non-permeabilizing conditions to
detect antibody-labeled receptor on the cell surface at the end of the drug stimulation
(“Cell Surface Labeling”) or under permeabilizing conditions to detect total primary
antibody-labeled receptor (“Total Cell Labeling”). Even following chronic agonist
stimulation, CB2 retains a recycling phenotype and is not degraded. Data was normalized
to the expression level of unstimulated cells and is presented as themeans±SEM of three
independent experiments.
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surface CB2 expression (t½ 3.3±0.3 hours, one-phase exponential
association; Fig. 5B).
3.4. Involvement of Rab GTPases in CB2 trafﬁcking
Investigation of the involvement of Rabs 4, 5 and 11 was performed
by transient transfection of each of the EGFP tagged Rab proteins in one
of three different states: (1) wild-type (WT), (2) constitutively active
(expressing a point mutation that renders the enzyme incapable of
hydrolyzing GTP), and (3) dominant negative (the Rabs exhibit a
mutation conveying preferential binding to GDP over GTP). Over-
expressionof theWTRabproteins did not inﬂuence any of the aspects of
CB2 trafﬁcking studied, as determined by comparison with cells
transfected with empty EGFP vector (p=0.9738).
Transient transfection with Rab5 GDP negatively inﬂuenced the
extent of agonist-induced internalization (p=0.0093; Fig. 6B) but did
not inﬂuence the proportion of receptors subsequently recycled
(p=0.7804; Fig. 6C). This is consistent with Rab5 being a mediator of
CB2 internalization. There was also a trend towards enhanced basal
cell surface expression in cells over-expressing this Rab suggesting it
may have also impaired constitutive internalization (Fig. 6A).
As expected, the extent of internalization of CB2 was not altered by
over-expression ofmutant Rab4 or 11 (p=0.5687–1; Fig. 6B). However,
the extent of recycling was signiﬁcantly decreased when Rab11 GDP
was over-expressed (p=0.0170; Fig. 6C). There was also a trend
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Fig. 5. Constitutive Trafﬁcking of CB2 in HEK-CB2 cells. (A) Surface receptor was labeled
with primary antibody, then allowed to constitutively internalize. Secondary antibodywas
applied under non-permeabilizing conditions to detect antibody-labeled receptor on the
cell surface at the end of the incubation (demonstrating constitutive internalization,□), or
under permeabilizing conditions to detect total primary antibody-labeled receptor
(demonstrating constitutive degradation,■). (B) Time course of surface CB2 upregulation
with 1 μM AM630. Surface receptors were detected by labeling with primary antibody at
the conclusion of drug treatment. (A and B) Data was normalized to surface receptor
expression level of cells treated with vehicle and ﬁxed immediately following labeling of
surface receptors (time 0) and is presented as the means±SEM of three independent
experiments.
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recycling in comparison with wild-type Rab11, although this did not
reach signiﬁcance (p=0.2242). In contrast, transient transfection with
dominant negative (Rab4 GDP) or dominant positive (Rab4 GTP) Rab4
did not signiﬁcantly alter the extent of recycling (p=1; Fig. 6C). None of
the Rab4 or 11 isoforms investigated signiﬁcantly inﬂuenced basal
surface CB2 expression (p=0.8038; Fig. 6A).
4. Discussion
Published material describing the trafﬁcking properties of CB2 is
scarce but clearly indicates these receptors are capable of undergoing
phosphorylation [2,3] and internalization with agonist stimulation
[2,4,5] or exposure toUVB rays [6]. CB2 has also been reported to exhibit
a degree of constitutive phosphorylation and activation, properties that
often correlate with constitutive internalization [2,20]. The present
ﬁndings support these observations and further characterize the
trafﬁcking properties of CB2 in an in vitro, heterologous expression
system.
CB2 was rapidly internalized after agonist exposure, as is consistent
withotherGPCRs [21]. The agonist-induced lossof receptor from thecell
surfacewith respect to time followed a rapid decay curve proﬁle similar
to that of CB1 [15]. However in the sameparent cell line, close to 100% of
CB1 can be induced to internalize [15], whereas here we show the
maximumextent of CB2 internalization is approximately 80%. Although
it might be suggested that saturation of trafﬁcking pathways wasreached in this cell line, similar results were found in various clones of
the mixed population exhibiting a range of overall expression levels, as
well as in Chinese hamster ovary cells also stably transfected with HA
tagged human CB2 (data not shown). This lack of complete internal-
ization is reminiscent of the effects of partial agonists on other GPCRs
[e.g., 22–24], and suggests that HU-308 might in fact act as a partial
agonist rather than a full agonist as it is sometimes deﬁned [e.g., 25,26].
We observed a signiﬁcant reduction in the capacity for CB2
internalization in the presence of dominant negative Rab5, clearly
demonstrating the involvement of this Rab in CB2 endocytosis. In
addition, a trend towards increased basal cell surface CB2 expression
when the dominant negative Rab5 was present supports our
observation of constitutive CB2 internalization and suggests both
agonist driven and constitutive CB2 internalization are mediated by
Rab5. The lack of inﬂuence of the Rab5 constructs on recycling also
indicates that alterations in the extent of internalization do not affect
the proportion of CB2 recycled in this model.
A prior report demonstrating the ability of CB2 to be repeatedly
phosphorylated and dephophorylated by alternate stimulation with
agonist and inverse agonist suggested that CB2 recycling may occur [2].
Here, we provide the ﬁrst direct evidence to support this hypothesis.
Following internalization we noted that CB2 was localized in both
diffuse puncta and a discrete perinuclear cluster in most cells.
Interestingly, this pattern resembles a mixture of the phenotypes
previously observed for CB1, a degrading receptor exhibiting diffuse
endosomes following agonist exposure, and dopamine receptor 1, a
receptor that recycles efﬁciently and is almost exclusively localized in a
perinuclear compartment following endocytosis [12]. On this basis it
might be deduced that not all endocytosed CB2 is delivered to recycling
compartments, and this is indeed consistentwith the extent of recycling
observed. Unexpectedly, although not all CB2 was recycled to the cell
surface, the remaining proportion of internalized CB2 did not degrade
and instead seemed to remain sequestered in the cytoplasm. This was
also the case following an extended period of agonist simulation.
Conversely, CB2 slow degradation was observed following constitutive
internalization. While this degradation likely represents cellular
turnover of receptors and is not unusual, it is intriguing that agonist
stimulation seemed to actively promote recycling and prevent CB2
degradation. The mechanisms and implications of this phenomenon
warrant further study.
Our data suggests that CB2 recycling following agonist-induced
internalization is mediated via a Rab11-dependent pathway, but does
not involve Rab4. While Rab4 appears to be predominantly important
for “rapid” recycling directly from early endosomes where receptors
have been observed to be reinserted in the plasma membrane within
minutes [11,27], Rab11 is generally understood to be required for
slower recycling via the perinuclear recycling compartment [13]. Our
observation that a proportion of internalized CB2 is localized to a
distinct perinuclear cluster is consistent with it being trafﬁcked via
the perinuclear recycling compartment and reinforces the conclusion
that CB2 undergoes Rab11-dependent recycling.
5. Conclusions
CB2 is under intense scrutiny as a mediator of cannabinoid related
effects with the potential to avoid the psychotropic complications
involved with activating CB1 receptors. Improved knowledge of the
cellular trafﬁcking properties of this receptor may prove beneﬁcial in
determining dosing regimes and understanding clinical outcomes. It is
apparent from the results obtained here that in transfected cell models
CB2 internalizes in response to agonist stimulation, a process involving
Rab5 for both constitutive and agonist driven internalization. CB2
recycling following agonist driven internalization involved Rab11 but
not Rab4, suggesting recycling occurs through the perinuclear recycling
compartment, rather than fast recycling pathway directly from early
endosomes. Here we have provided an initial characterization of CB2
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10 μMAM630 for 60 minutes. Recycling was enhanced by Rab11 GTP and inhibited by Rab11 GDP. Data is presented as the means±SEM of three to ﬁve independent experiments.
*pb0.05; ***pb0.001.
1559N.L. Grimsey et al. / Biochimica et Biophysica Acta 1813 (2011) 1554–1560recycling in response to the selective agonist HU-308. Future avenues
for investigation will be to study trafﬁcking of endogenously expressed
CB2 and further deﬁne key regulatory proteins involved in this process.
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